Tag: KDC-MN-095

  • Rapamycin (Sirolimus)

    mTOR inhibitor / immunosuppressant

    A bacterial macrolide isolated from Streptomyces hygroscopicus, FDA-approved as an immunosuppressant and increasingly investigated for longevity applications through mTOR inhibition.

    Abstract

    Rapamycin (Sirolimus, Rapamune; CAS 53123-88-9; molecular formula C51H79NO13; molecular weight 914.17) is a macrolide compound isolated in 1972 from Streptomyces hygroscopicus from Easter Island (Rapa Nui, providing the name). The compound was approved by the FDA in 1999 as an immunosuppressant for renal transplantation. Mechanism is selective inhibition of mTORC1 (mammalian target of rapamycin complex 1) through binding to FKBP12 and forming a complex that allosterically inhibits mTOR kinase activity. Beyond immunosuppression, rapamycin extends lifespan in multiple model organisms (yeast, worms, flies, mice) when administered late in life, making it the most extensively documented pharmacological intervention for lifespan extension. The Interventions Testing Program (ITP) at NIA showed reproducible lifespan extension in genetically heterogeneous mice. Mechanisms of lifespan extension include reduced cellular senescence, improved autophagy, attenuation of age-related inflammation, and reduced age-related cancer incidence. Pharmacokinetics: plasma half-life 60 to 70 hours; high oral bioavailability; CYP3A4 metabolism.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.